Figure 2.

Sorafenib ameliorates bleomycin (BLM)-induced pulmonary fibrosis in vivo. Mice were treated with 3.5 mg/kg BLM once at day 0 and subsequently received sorafenib (5 mg/kg) or vehicle by gavage once per day for 12 days (from days 3 to 14). (a) Pulmonary tissue sections were prepared at day 14 and stained with hematoxylin and eosin (H&E) for routine examination. (b and c) The sections were also subjected to Sirius red or Masson's trichrome staining for the visualization of collagen deposition. (d) The hydroxyproline (Hyp) content of the pulmonary tissues (n=5 for each group) was measured at day 28 and is presented as micrograms of Hyp per gram of wet weight (μg/g). (e) Real-time PCR was performed to detect the expression of CCN-2 and TGF-β1 in the pulmonary tissues from each group. **P<0.01; as determined using Student's t-test